[go: up one dir, main page]

DK1287364T3 - Diagnostisk og terapi til makulære degenerationsrelaterede lidelser - Google Patents

Diagnostisk og terapi til makulære degenerationsrelaterede lidelser

Info

Publication number
DK1287364T3
DK1287364T3 DK01934962T DK01934962T DK1287364T3 DK 1287364 T3 DK1287364 T3 DK 1287364T3 DK 01934962 T DK01934962 T DK 01934962T DK 01934962 T DK01934962 T DK 01934962T DK 1287364 T3 DK1287364 T3 DK 1287364T3
Authority
DK
Denmark
Prior art keywords
macular degeneration
related disorders
diagnostic
therapy
treating
Prior art date
Application number
DK01934962T
Other languages
English (en)
Inventor
Gregory S Hageman
Robert F Mullins
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22742799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1287364(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of DK1287364T3 publication Critical patent/DK1287364T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
DK01934962T 2000-04-29 2001-04-30 Diagnostisk og terapi til makulære degenerationsrelaterede lidelser DK1287364T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20069800P 2000-04-29 2000-04-29
PCT/US2001/013971 WO2001084149A2 (en) 2000-04-29 2001-04-30 Diagnostics and therapeutics for macular degeneration-related disorders

Publications (1)

Publication Number Publication Date
DK1287364T3 true DK1287364T3 (da) 2009-03-02

Family

ID=22742799

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08162987.5T DK2026073T3 (da) 2000-04-29 2001-04-30 Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser
DK01934962T DK1287364T3 (da) 2000-04-29 2001-04-30 Diagnostisk og terapi til makulære degenerationsrelaterede lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08162987.5T DK2026073T3 (da) 2000-04-29 2001-04-30 Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser

Country Status (10)

Country Link
US (5) US20020015957A1 (da)
EP (2) EP2026073B1 (da)
JP (1) JP4764590B2 (da)
AT (1) ATE412185T1 (da)
AU (2) AU2001261103B2 (da)
CA (1) CA2407715C (da)
DE (1) DE60136272D1 (da)
DK (2) DK2026073T3 (da)
ES (1) ES2316446T3 (da)
WO (1) WO2001084149A2 (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7108982B1 (en) * 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001261103B2 (en) * 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
SE0100595D0 (sv) * 2001-02-22 2001-02-22 Lena Carlsson Immunological detection of prostate diseases and prostatic-related diseases
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
EP2292259A3 (en) * 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
JP4269064B2 (ja) * 2003-02-26 2009-05-27 国立大学法人 千葉大学 重症筋無力症の検査方法及びそのための検査薬
JPWO2004096277A1 (ja) * 2003-05-01 2006-07-13 国立大学法人京都大学 眼内血管新生疾患の予防又は治療剤
PT2374819T (pt) * 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
AU2005214040B2 (en) * 2004-02-12 2011-03-31 Neo Vista, Inc. Methods and apparatus for intraocular brachytherapy
US20050250745A1 (en) * 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
EP2446902A1 (en) * 2004-06-10 2012-05-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP2006528361A (ja) 2004-07-06 2006-12-14 クンイル ファーマシューティカル カンパニー リミテッド アルドラーゼを含む網膜血管疾患診断用組成物およびその診断方法
WO2006042252A2 (en) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US20090017029A1 (en) * 2004-11-18 2009-01-15 Yale University Methods and Compositions for Treating Ocular Disorders
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US20070037183A1 (en) * 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
EP1861114B1 (en) * 2005-03-11 2011-02-02 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
BRPI0618160A2 (pt) * 2005-05-26 2011-08-16 Univ Colorado inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas
EP1929037A4 (en) * 2005-08-24 2009-07-22 Cy O Connor Erade Village Foun IDENTIFICATION OF ANCESTRAL HAPLOTYPES AND USES THEREOF
WO2007032876A2 (en) * 2005-09-09 2007-03-22 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN103505718B (zh) * 2005-10-08 2018-11-23 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
MX360959B (es) * 2005-11-04 2018-11-23 Genentech Inc Uso de inhibidores de la vía del complemento para tratar enfermedades oculares.
CA2629648A1 (en) 2005-11-15 2007-05-24 Neovista Inc. Methods and apparatus for intraocular brachytherapy
EP1963529A2 (en) * 2005-12-22 2008-09-03 Alcon Research, Ltd. C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) * 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
PL2596807T3 (pl) * 2006-03-08 2016-06-30 Archemix Llc Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych
WO2007118095A2 (en) * 2006-04-03 2007-10-18 University Of Iowa Research Foundation Binding of complement factor h to c-reactive protein
EP2826788B1 (en) 2006-06-21 2017-12-13 MUSC Foundation for Research Development Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules
NZ574046A (en) 2006-07-13 2012-09-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
CA2661161A1 (en) * 2006-08-23 2008-02-28 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
RU2474589C9 (ru) 2006-11-02 2019-08-15 Дженентек, Инк. Гуманизированные антитела к фактору d и их применения
WO2008091617A2 (en) * 2007-01-23 2008-07-31 Case Western Reserve University Method for detecting age related macular degeneration in a subject
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
US7972787B2 (en) 2007-02-16 2011-07-05 Massachusetts Eye And Ear Infirmary Methods for detecting age-related macular degeneration
NZ578873A (en) * 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
WO2008140653A2 (en) 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
US20100015139A1 (en) * 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
KR20100014486A (ko) * 2007-04-30 2010-02-10 알콘 리서치, 리미티드 보체 인자 ｄ의 저해제를 사용한 연령 관련 황반변성의 치료
US20110311532A1 (en) * 2007-08-29 2011-12-22 Rekha Bansal Inhibition of complement and cellular activation
CA2715373C (en) * 2008-02-15 2019-11-05 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
AU2015202046B2 (en) * 2008-02-15 2017-06-29 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP2011522603A (ja) 2008-06-04 2011-08-04 ネオビスタ、インコーポレイテッド 放射線源ワイヤを前進させるための手持ち放射線送達システム
DK2328616T3 (da) 2008-08-05 2015-07-20 Novartis Ag Sammensætninger og fremgangsmåder for antistoffer mod komplementprotein C5
GB0816702D0 (en) * 2008-09-12 2008-10-22 Trinity College Dublin Complement proteins
WO2010129351A1 (en) * 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2451983B1 (en) 2009-07-10 2015-05-06 The Regents of the University of Michigan Methods for diagnosing macular degeneration
US20120190578A1 (en) * 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
PT2488203T (pt) * 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
WO2011053774A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
RU2657515C2 (ru) * 2010-04-13 2018-06-14 м-лаб ГмбХ Способы диагностики глаукомы
KR20130080443A (ko) 2010-05-14 2013-07-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 개선된 보체 수용체 ２(ｃｒ２) 표적 그룹들
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
WO2012040619A2 (en) 2010-09-24 2012-03-29 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
AU2011336702B2 (en) 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
KR101256908B1 (ko) * 2011-04-28 2013-04-23 (주)에이치비메디컬스 주름제거용 충전체
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
JP2015523546A (ja) * 2012-05-01 2015-08-13 トランスレイタム メディカス インコーポレイテッド 失明性疾患を処置および診断するための方法
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
ES2780674T3 (es) 2012-11-15 2020-08-26 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
US9138466B2 (en) 2013-03-14 2015-09-22 Baxalta Incorporated Factor H for transplantation
WO2014151923A1 (en) 2013-03-14 2014-09-25 Baxter International Inc. Factor h for treatment of rheumatoid arthritis
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2016139662A1 (en) 2015-03-01 2016-09-09 Improved Vision Systems (I.V.S.) Ltd. A system and method for measuring ocular motility
EP3115784A1 (en) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
IL258525B2 (en) 2015-10-07 2023-03-01 Apellis Pharmaceuticals Inc Dosing regimens
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
WO2017136805A1 (en) * 2016-02-06 2017-08-10 Georgetown University Compositions and methods for the diagnosis and treatment of age-related macular degeneration
WO2017208227A1 (en) * 2016-05-29 2017-12-07 Nova-Sight Ltd. Display system and method
WO2018055618A1 (en) 2016-09-23 2018-03-29 Novasight Ltd. Screening apparatus and method
ES2848206T3 (es) * 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
EP3529619B1 (en) * 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
WO2019006153A1 (en) * 2017-06-30 2019-01-03 Anthrobio IMPROVEMENT OF THE PROTEOLYTIC CASCADE FOR THE TREATMENT OF A DISEASE
EP3655545B1 (en) 2017-07-18 2023-10-18 The Research Foundation for The State University of New York Biomarkers for intracranial aneurysm
US11753382B2 (en) 2019-06-25 2023-09-12 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
EP4003392A4 (en) * 2019-07-26 2023-08-09 Allegro Pharmaceuticals, LLC PEPTIDES FOR THE TREATMENT OF NON-EXCESSIVE MACULAR DEGENERATION AND OTHER EYE DISEASES

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US102581A (en) * 1870-05-03 Improvement in boiler-furnaces
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3650090A (en) * 1970-06-19 1972-03-21 Phillips Petroleum Co Analysis of gaseous mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5506247A (en) 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018980A1 (en) 1990-06-01 1991-12-12 Cetus Corporation Compositions and methods for identifying biologically active molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU686579B2 (en) 1992-10-01 1998-02-12 Cold Spring Harbor Laboratory Complex combinatorial chemical libraries encoded with tags
EP1262564A3 (en) 1993-01-07 2004-03-31 Sequenom, Inc. Dna sequencing by mass spectrometry
JP3689422B2 (ja) 1993-02-12 2005-08-31 アーヴァント イミュノセラピューティクス インコーポレイテッド ｓＣＲ１およびその他の補体阻害蛋白の肺内投与
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5583973A (en) 1993-09-17 1996-12-10 Trustees Of Boston University Molecular modeling method and system
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
US5681571A (en) 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
WO1995012608A1 (en) 1993-11-02 1995-05-11 Affymax Technologies N.V. Synthesizing and screening molecular diversity
AU1441395A (en) * 1993-12-21 1995-07-10 St. Louis University Ocular diagnostics and therapies
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP0758313A4 (en) 1994-05-06 1999-09-15 Pharmacopeia Inc COMBINATORIAL LIBRARY OF DIHYDROBENZOPYRANES
GB2290293A (en) 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5612894A (en) 1995-02-08 1997-03-18 Wertz; David H. System and method for molecular modeling utilizing a sensitivity factor
US6103235A (en) 1995-10-30 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
JPH09194393A (ja) 1996-01-22 1997-07-29 Meiji Milk Prod Co Ltd 免疫寛容を誘導する方法、免疫寛容誘導食品キットおよび免疫寛容誘導剤キット
WO1997028276A1 (en) 1996-02-02 1997-08-07 Stichting Onderzoeksbeleid Cardiopulmonale Chirurgie Measurement of complement activation by biomaterials by means of complement convertase cleavage of peptide substrates
PL187733B1 (pl) 1996-02-26 2004-09-30 Advanced Res & Tech Inst Zastosowanie inhibitora anhydrazy węglanowej
US5843449A (en) 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
WO1997038004A1 (en) 1996-04-10 1997-10-16 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
US5705380A (en) 1996-09-04 1998-01-06 Sequana Theraputics, Inc. Identification of a gene encoding TULP2, a retina specific protein
US5686598A (en) 1996-08-22 1997-11-11 The Jackson Laboratory Genes associated with retinal dystrophies
US6102236A (en) * 1997-01-31 2000-08-15 Tetra Laval Holdings & Finance S.A. Lid of a container for beverages
US5773673A (en) * 1997-07-01 1998-06-30 Occidental Chemical Corporation Method of making chlorinated hydrocarbons
ATE291097T1 (de) 1997-10-31 2005-04-15 Affymetrix Inc A Delaware Corp Expressionsprofile in adulten und fötalen organen
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US7108982B1 (en) * 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
CA2363503C (en) 1999-03-05 2009-03-10 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
RU2474589C9 (ru) * 2006-11-02 2019-08-15 Дженентек, Инк. Гуманизированные антитела к фактору d и их применения
AU2008251801A1 (en) * 2007-05-11 2008-11-20 The General Hospital Corporation Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento

Also Published As

Publication number Publication date
EP2026073B1 (en) 2016-03-30
US20030207309A1 (en) 2003-11-06
US20180335436A1 (en) 2018-11-22
EP1287364A2 (en) 2003-03-05
US20020015957A1 (en) 2002-02-07
ATE412185T1 (de) 2008-11-15
EP2026073A1 (en) 2009-02-18
CA2407715C (en) 2009-03-24
CA2407715A1 (en) 2001-11-08
JP2003535581A (ja) 2003-12-02
DE60136272D1 (de) 2008-12-04
US20110182908A1 (en) 2011-07-28
US20060263819A1 (en) 2006-11-23
WO2001084149A3 (en) 2002-07-18
AU6110301A (en) 2001-11-12
AU2001261103B2 (en) 2007-08-23
EP1287364B1 (en) 2008-10-22
DK2026073T3 (da) 2016-07-25
WO2001084149A2 (en) 2001-11-08
US7351524B2 (en) 2008-04-01
JP4764590B2 (ja) 2011-09-07
ES2316446T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
ITRE20000134A0 (it) Metodo e dispositivo per la diagnosi e la terapia dello scompenso cardiaco cronico.
AU7494701A (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
BR0007720A (pt) Porfirinas substituìdas
EP1638443A4 (en) ISOFORMS OF BRAIN NATRIURETIC PEPTIDE
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
HK1069767A1 (en) Methods for inhibiting ocular processes
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
NL1021504A1 (nl) Waterstofbehandelingsproces.
EP1254260A4 (en) METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
AT500370B8 (de) Verfahren zum diagnostizieren, verhindern und behandeln neurodegenerativer erkrankungen